Abstract:BACKGROUND. Clinical investigations have shown that in patients with breast carcinoma, tumors that overexpress the erb-B2 gene are less responsive to certain chemotherapy regimens compared with tumors that express low levels of ErbB2, Suggesting that ErbB2 overexpression may be used as a marker for poor response to chemotherapy in patients with breast carcinoma. The combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) is one of the most widely used chemotherapy regimens in patients with breast carcinoma. Patients who have ErbB2-overexpressing breast carcinomas have poorer responses to CMF compared with patients who have breast carcinomas with low ErbB2 expression. ErbB2-overexpressing breast tumor cells are resistant to taxol-induced apoptotic cell death. The underlying molecular mechanism is that ErbB2 inhibits p34(Cdc2) activation, which is required for taxol-induced apoptosis, by up-regulating p21(Cip1) and by hyperphosphorylating p34(Cdc2),2 on tyrosine-15. However, the relation between ErbB2, p21(Cip1), and p34(Cdc2) in patients with breast carcinoma remains elusive. The contribution of these molecular alterations to ErbB2-mediated CMF resistance has not been examined.METHODS. Formalin-fixed, paraffin-embedded, 5 mum thick tissue sections from 107 patients with invasive breast carcinoma were immunostained using specific antibodies against ErbB2, p21(Cip1), and phosphorylated tyrosine (Tyr)-15 of p34(Cdc2). Ninety-four of 107 patients were treated with the CMF regimen. In situ hybridization of p21(Cip1)mRNA also was performed in 20 of the sections described above. ErbB2 expression levels, p21(Cip1) expression levels, and phosphorylation status on Tyr15 of p34(Cdc2) were analyzed for correlations with clinicopathologic parameters for the 107 patients and for correlations with disease-free survival (DFS) in the 94 patients who were treated with the CMF regimen.RESULTS. Among 94 patients with breast carcinoma who were treated with CMF, it was found that ErbB2 overexpression was associated significantly with poor DFS (P < 0.01). Patients who had higher p21(Cip1) expression had worse DFS compared with patients who had low p21(Cip1) expression (P = 0.02). However, no significant correlation was found between p34(Cdc2)-Tyr15 phosphorylation and DFS (P > 0.05). It is noteworthy that p21(Cip1) expression and p34(Cdc2)-Tyr15 phosphorylation were correlated significantly and positively with Erb132 expression (P < 0.01).CONCLUSIONS. The current study suggests that p21(Cip1) expression, but not p34(Cdc2)- Tyr15 phosphorylation, may play a role in ErbB2-mediated CMF resistance, which may contribute to the poor survival of patients with ErbB2-overexpressing breast carcinomas who were treated on the CMF regimen. In addition, Erb132 overexpression was correlated with P21(Cip1) up-regulation and with increased p34(Cdc2)-Tyr15 phosphorylation in breast tumors. &COPY; 2003 American Cancer Society.

ErbB2/HER2 governs CDK4 inhibitor sensitivity and timing and irreversibility of G1/S transition by altering c-Myc and cyclin D function

Slower CDK4 and faster CDK2 activation in the cell cycle

Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells

Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer

Abstract P3-10-01: Deciphering the heterogeneity of cell cycle in breast cancer and relevance to clinical application of CDK inhibitors

The G1/S transition is promoted by Rb degradation via the E3 ligase UBR5

The Requirement for Cyclin E in C-Myc Overexpressing Breast Cancers.

C-Myb Regulates Cell Cycle-Dependent Expression of Erbin: an Implication for a Novel Function of Erbin.

Cyclin G2 promotes cell cycle arrest in breast cancer cells responding to fulvestrant and metformin and correlates with patient survival

Cell cycle, CDKs and cancer: a changing paradigm

Mechanisms of sensitivity and resistance to CDK4/CDK6 inhibitors in hormone receptor-positive breast cancer treatment

APC/C prevents a noncanonical order of cyclin/CDK activity to maintain CDK4/6 inhibitor-induced arrest

Cyclin D- and E-Dependent Kinases and the P57(Kip2) Inhibitor: Cooperative Interactions in Vivo

The oscillation of mitotic kinase governs cell cycle latches in mammalian cells

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer

Chemotherapy modulates CDK4/6 inhibitors resistance in metastatic breast cancer by Rb1 mutations: a case report and literature review

EGFR-mediated G1/S Transition Contributes to the Multidrug Resistance in Breast Cancer Cells

Coordinate regulation of estrogen receptor β degradation by Mdm2 and CREB-binding protein in response to growth signals

C-Src Regulates Cell Cycle Proteins Expression Through Protein Kinase B/glycogen Synthase Kinase 3 Beta and Extracellular Signal-Regulated Kinases 1/2 Pathways in MCF-7 Cells